钙周期素结合蛋白对乳癌新辅助化疗效果的预测价值  

VALUE OF CALCYCLIN-BINDING PROTEIN IN PREDICTING THE EFFICACY OF NEOADJUVANT CHEMOTHERAPY FOR BREAST CANCER

作　　者：崔茹婷 吕志栋[1] 姚瑶[1] 张蔚然 孔滨 CUI Ruting;L Zhidong;YAO Yao;ZHANG Weiran;KONG Bin(Diagnosis and Treatment Centre of Breast Diseases,The Affiliated Hospital of Qingdao University,Qingdao 266100,China)

机构地区：[1]青岛大学附属医院乳腺病诊疗中心,山东青岛266100

出　　处：《青岛大学学报（医学版）》2022年第5期714-719,共6页Journal of Qingdao University(Medical Sciences)

基　　金：中国博士后基金面上项目(2020M672001);山东省自然科学基金面上项目(ZR2020MH274);山东省医药卫生发展计划项目(2019WS112)。

摘　　要：目的探讨乳癌病人钙周期素结合蛋白(CacyBP/SIP)的表达及其与新辅助化疗效果和生存预后的关系。方法回顾性选取2015年1月—2016年6月于青岛大学附属医院行新辅助化疗的乳癌病人70例,采用EnVision免疫组化法检测新辅助化疗前穿刺确诊标本CacyBP/SIP的表达,结合重要的临床病理学参数,统计分析CacyBP/SIP与新辅助化疗效果和预后的关系。结果CacyBP/SIP在组织学分级高、有淋巴结转移、临床分期晚、人类表皮生长因子受体-2(HER-2)阳性的乳癌组织中高表达(χ2=4.444~6.806,P<0.05)。二元Logistic回归分析结果显示,雌激素受体(ER)阴性(OR=0.132,95%CI=0.028~0.789,P=0.025)、HER-2阳性(OR=5.210,95%CI=1.685~27.135,P=0.004)、CacyBP/SIP低表达(OR=0.169,95%CI=0.033~0.859,P=0.039)与病人更好的新辅助化疗效果相关。Kaplan-Meier法分析显示,CacyBP/SIP低表达组病人5年无病生存率明显高于高表达组(Log-rankχ2=4.598,P=0.032)。多因素COX回归分析显示,客观缓解(HR=0.151,95%CI=0.042~0.451,P=0.004)是乳癌预后的独立保护因子,而CacyBP/SIP不是乳癌新辅助化疗的独立预后因子。结论CacyBP/SIP异常上调与乳癌恶性进展关系密切,可作为新辅助化疗后病理完全缓解的独立预测指标。Objective To investigate the expression of calcyclin-binding protein(CacyBP/SIP)in breast cancer patients and its association with neoadjuvant chemotherapy efficacy and survival prognosis.Methods A retrospective analysis was performed for 70 breast cancer patients who received neoadjuvant chemotherapy in The Affiliated Hospital of Qingdao University from January 2015 to June 2016.EnVision immunohistochemistry was used to measure the expression of CacyBP/SIP in puncture specimens before neoadjuvant chemotherapy,and the association of CacyBP/SIP with chemotherapy efficacy and prognosis was analyzed with reference to important clinicopathological parameters.Results CacyBP/SIP was highly expressed in breast cancer tissue with a high histological grade,lymph node metastasis,late clinical stage,and positive human epidermal growth factor receptor 2(HER-2)(χ2=4.444-6.806,P<0.05).The binary logistic regression analysis showed that negative estrogen receptor(OR=0.132,95%CI=0.028-0.789,P=0.025),positive HER-2(OR=5.210,95%CI=1.685-27.135,P=0.004),and low expression of CacyBP/SIP(OR=0.169,95%CI=0.033-0.859,P=0.039)were associated with the better efficacy of neoadjuvant chemothe-rapy.The Kaplan-Meier analysis showed that the patients with low CacyBP/SIP expression had a significantly higher 5-year di-sease-free survival rate than those with high CacyBP/SIP expression(log-rankχ2=4.598,P=0.032).The multivariate COX regression analysis showed that objective response(HR=0.151,95%CI=0.042-0.451,P=0.004)was an independent protective factor for the prognosis of breast cancer,while CacyBP/SIP was not an independent prognostic factor for neoadjuvant chemotherapy for breast cancer.Conclusion Abnormal upregulation of CacyBP/SIP is closely associated with the malignant progression of breast cancer,and CacyBP/SIP may be used as an independent predictive factor for pathological complete response after neoadjuvant chemotherapy.

关 键 词：乳房肿瘤 S100蛋白质类 放化疗 辅助 治疗结果 预后 

分 类 号：R737.9[医药卫生—肿瘤]